In fact, existing data suggest that only around 1 in 5 patients with early-stage BC achieve pCR after NACT, with the highest pCR rates observed among HER2-positive and TNBC cases, while HR+/HER2-negative tumors usually show the lowest (35, 36). The gene discussed is ERBB2; the disease is breast cancer.